display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
locally advanced (laHNSCC)
laHNSCC - 1st line (L1)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Head and Neck 100

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons